nih-gov/www.grants.nih.gov/grants/guide/pa-files/PA-02-015.html

585 lines
No EOL
28 KiB
HTML

<!-- Changed ON 09/24/2024 -->
<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-T2DH393N');</script>
<!-- End Google Tag Manager -->
<HTML lang="en-US">
<HEAD>
<!-- From DocTemplateOld.txt -->
<TITLE>Expired PA-02-015: ROLE OF LIMBIC SYSTEM AND BRAIN ONTOGENY IN DRUG ABUSE</TITLE>
<META NAME="description" CONTENT="NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: ROLE OF LIMBIC SYSTEM AND BRAIN ONTOGENY IN DRUG ABUSE PA-02-015. NIDA">
<META NAME="Keywords" CONTENT="PA-02-015: ROLE OF LIMBIC SYSTEM AND BRAIN ONTOGENY IN DRUG ABUSE">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000">
<link type="text/css" href="../guide_styles/css/oldGuideStyle.css" rel="stylesheet" media="all">
<link type="text/css" href="../guide_styles/css/expired.css" rel="stylesheet" media="all">
<div class="noticeBar">This notice has expired. Check the <a href="https://grants.nih.gov/funding/searchguide/">NIH Guide</a> for active opportunities and notices.</div>
<div id="watermark_background">
<p id="watermark_text">EXPIRED</p>
</div>
<pre>
This Program Announcement (PA) expires on October 31, 2004, unless reissued.
ROLE OF LIMBIC SYSTEM AND BRAIN ONTOGENY IN DRUG ABUSE
Release Date: October 19, 2001
PA NUMBER: PA-02-015
<a href="//grants.nih.gov/grants/guide/notice-files/NOT-OD-06-046.html">March 2, 2006</a> (NOT-OD-06-046) Effective with the June 1, 2006 submission date,
all R03, R21, R33 and R34 applications must be submitted through <a href="http://www.grants.gov/">Grants.gov</a> using
the electronic SF424 (R&amp;R) application. A Replacement R21 (<a href="//grants.nih.gov/grants/guide/pa-files/PA-06-445.html">PA-06-445</a>) funding
opportunity announcement has been issued for the submission date of June 1, 2006
and submission dates thereafter. In addition, a replacement R01 (<a href="//grants.nih.gov/grants/guide/pa-files/PA-06-444.html">PA-06-444</a>) has
been issued.
EXPIRATION DATE: October 31, 2004
National Institute on Drug Abuse
(<a href="http://www.nida.nih.gov">http://www.nida.nih.gov</a>)
THIS PA USES "MODULAR GRANT" AND "JUST-IN-TIME" CONCEPTS. MODULAR
INSTRUCTIONS MUST BE USED FOR RESEARCH GRANT APPLICATIONS UP TO
$250,000 PER YEAR. MODULAR BUDGET INSTRUCTIONS ARE PROVIDED IN SECTION
C OF THE PHS 398 (REVISION 5/2001) AVAILABLE AT
<a href="//grants.nih.gov/grants/funding/phs398/phs398.html">http://grants.nih.gov/grants/funding/phs398/phs398.html</a>.
PURPOSE
This version will replace in its entirety, PA-98-032, Role of Limbic
System and Brain Ontogeny in Drug Abuse, published in the NIH Guide
February 25, 1998.
Specific cortical and subcortical forebrain structures, often referred
to as the limbic system, play a significant role in mediating emotional
and motivated behavior as well as memory storage. The proper
development of forebrain structures and the formation of neural
circuitry in the forebrain are essential for the normal development of
pathways that mediate the hedonic properties of food, sex, and drugs of
abuse. Elucidation of the processes underlying the development of the
limbic system may provide critical insights into the adaptive processes
associated with addiction and provide insights into mechanisms that
might underlie increased vulnerability to addiction. This initiative
is designed to support basic research into the fundamental mechanisms
of development of the midbrain and basal forebrain structures that
mediate the euphoric properties of drugs as well as understanding how
drugs of abuse affect the cellular and molecular mechanism underlying
nervous system development. In the past, vertebrate model systems
(such as chick, frog, mouse, and zebrafish) and invertebrate systems
(such as Drosophila and C. Elegans) have provided insights into
mechanisms of development and are also likely to provide new
information about the formation and specification of the limbic system.
Approaches using these or other model systems both in vitro and in vivo
are applicable to this program announcement.
HEALTHY PEOPLE 2010
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2010," a
PHS led national activity for setting priority areas. This PA, Role of
Limbic System and Brain Ontogeny in Drug Abuse, is related to one or
more of the priority areas. Potential applicants may obtain a copy of
"Healthy People 2010" at <a href="https://www.health.gov/healthypeople/">http://www.health.gov/healthypeople/</a>.
ELIGIBILITY REQUIREMENTS
Applications may be submitted by domestic and foreign, for-profit and
non-profit organizations, public and private, such as, universities,
colleges, hospitals, laboratories, units of state and local
governments, and eligible agencies of the Federal government.
Racial/ethnic minority individuals, women, and persons with
disabilities are encouraged to apply as principal investigators.
MECHANISM OF SUPPORT
This PA will use the National Institutes of Health (NIH) research
project grant (R01) and exploratory/developmental grant (R21) award
mechanisms. Responsibility for the planning, direction, and execution
of the proposed project will be solely that of the applicant. The
research project grant (R01) application may not exceed 5 years. An
exploratory/developmental (R21) application is limited to 3 years. The
R21 mechanism is intended to encourage exploratory research projects
with sound methodology and strong rationales in underdeveloped areas of
drug abuse, and is limited in direct cost amounts of $100,000 per year.
Specific information on this research mechanism can be obtained from
NIDA&rsquo;s homepage (www.nida.nih.gov/funding.html).
Specific application instructions have been modified to reflect
"MODULAR GRANT" and "JUST-IN-TIME" streamlining efforts that have been
adopted by the NIH. Complete and detailed instructions and information
on Modular Grant applications have been incorporated into the PHS 398
(rev. 5/2001). Additional information on Modular Grants can be found
at <a href="//grants.nih.gov/grants/funding/modular/modular.htm">http://grants.nih.gov/grants/funding/modular/modular.htm</a>.
RESEARCH OBJECTIVES
Examples of research that may be considered responsive to this program
announcement include, but are not limited to, those listed below. In
all research areas, investigators are encouraged to analyze
developmental mechanisms that contribute to sexual dimorphisms.
Neural Induction and Pattern Formation.
o Studies on the cellular and molecular mechanisms by which the
midbrain, nucleus accumbens, striatum, prefrontal cortex and limbic
area are specified from neural ectoderm including regionalization of
gene transcription, cell-cell interaction, and secreted signals that
influence these processes.
o How psychostimulants (cocaine, amphetamine, etc.), opiates,
barbiturates, hallucinogens, benzodiazepines, cannabinoids, inhalants,
and any other class of abused drugs affect the cellular and molecular
mechanisms of neural induction and pattern formation.
Stem Cells and Progenitors.
o The cellular and molecular mechanisms of stem cell and progenitor
cell induction, proliferation, and phenotypic restriction in the
midbrain, nucleus accumbens, striatum, prefrontal cortex and limbic
regions of the brain.
o Studies on how abused drugs influence fundamental processes
controlling stem cell, progenitor cell induction, and phenotypic
restriction in all parts of the nervous system.
Cell Fate and Specification.
o The mechanisms by which neuronal and glial cell fate is specified by
cell-cell interaction, growth factor, cytokines, hormones, and by
neurotransmitters in the midbrain, nucleus accumbens, striatum,
prefrontal cortex, and limbic regions.
o How drugs of abuse modulate the molecular mechanisms are involved in
determining cell fate and specifications in all brain regions.
Neural and Glial Differentiation.
o The transcriptional and post-transcriptional regulation of the
acquisition of the differentiated phenotype of dopamine neurons in the
ventral tegmental area and substantia nigra, as well as neurons and
glia in the midbrain, nucleus accumbens, striatum, prefrontal cortex,
and limbic areas (including cell morphology, excitability, growth
factor responsiveness, and expression of neurotransmitters and
receptors).
o The molecular and cellular processes by which drugs of abuse alter
neuronal differentiation by interrupting or augmenting the signal
transduction mechanisms involved in the acquisition of the
differentiated neuronal and glial phenotypes in all brain regions.
Cell Migration.
o The cellular and molecular substrates that direct and guide glial
and neuronal migration in the areas that form the midbrain, nucleus
accumbens, striatum, prefrontal cortex, and limbic areas.
o How drugs of abuse modulate or alter fundamental mechanisms are
involved in cell migration in all areas of the brain.
Process Outgrowth, Navigation, and Target Selection.
o The cellular and molecular mechanisms that regulate dendritic and
axonal outgrowth, navigation, and target selection (including axonal
guidance, branching, fasciculation, the formation of topographic and
laminar-specific projections in the midbrain, nucleus accumbens,
striatum, prefrontal cortex and limbic areas).
o How drugs of abuse affect the fundamental cellular mechanisms
mediating process outgrowth, navigation, and target selection in all
areas of the brain.
Synapse Formation and Plasticity During Development.
o The cellular and molecular mechanisms governing the formation of
synapses and developmental plasticity as well as the role of cell-cell
recognition molecules, growth factors, electrical activity, and
experience in the development of the midbrain, nucleus accumbens,
striatum, prefrontal cortex, and limbic systems.
o Analysis of how abused drugs affect the cellular and molecular
mechanisms governing the formation of synapses and developmental
plasticity throughout the central and peripheral nervous system.
Programmed Cell Death.
o Investigations into the cellular and molecular mechanisms of
programmed cell death in the midbrain, nucleus accumbens, striatum,
prefrontal cortex, and limbic systems during development.
o Investigations on how abused drugs may modulate signal transduction
pathways that mediate cell survival and cell death in vertebrate and
invertebrate systems.
INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS
It is the policy of the NIH that women and members of minority groups
and their sub-populations must be included in all NIH-supported
biomedical and behavioral research projects involving human subjects,
unless a clear and compelling rationale and justification are provided
indicating that inclusion is inappropriate with respect to the health
of the subjects or the purpose of the research. This policy results
from the NIH Revitalization Act of 1993 (Section 492B of Public Law
103-43).
All investigators proposing research involving human subjects should
read the UPDATED "NIH Guidelines for Inclusion of Women and Minorities
as Subjects in Clinical Research," published in the NIH Guide for
Grants and Contracts on August 2, 2000
(<a href="//grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html">http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html</a>. A
complete copy of the updated Guidelines is available at
<a href="//grants.nih.gov/grants/funding/women_min/guidelines_update.htm">http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm</a>.
The revisions relate to NIH defined Phase III clinical trials and
require: a) all applications or proposals and/or protocols to provide a
description of plans to conduct analyses, as appropriate, to address
differences by sex/gender and/or racial/ethnic groups, including
subgroups if applicable, and b) all investigators to report accrual,
and to conduct and report analyses, as appropriate, by sex/gender
and/or racial/ethnic group differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS
It is the policy of NIH that children (i.e., individuals under the age
of 21) must be included in all human subjects research, conducted or
supported by the NIH, unless there are scientific and ethical reasons
not to include them. This policy applies to all initial (Type 1)
applications submitted for receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should
read the "NIH Policy and Guidelines on the Inclusion of Children as
Participants in Research Involving Human Subjects" that was published
in the NIH Guide for Grants and Contracts, March 6, 1998, and is
available at the following URL address:
<a href="//grants.nih.gov/grants/guide/notice-files/not98-024.html">http://grants.nih.gov/grants/guide/notice-files/not98-024.html</a>.
Investigators also may obtain copies of these policies from the program
staff listed under INQUIRIES. Program staff may also provide
additional relevant information concerning the policy.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS
NIH policy requires education on the protection of human subject
participants for all investigators submitting NIH proposals for
research involving human subjects. This policy announcement is found
in the NIH Guide for Grants and Contracts Announcement dated June 5,
2000, at the following website:
<a href="//grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html">http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html</a>.
URLS IN NIH GRANT APPLICATIONS OR APPENDICES
All applications and proposals for NIH funding must be self-contained
within specified page limitations. Unless otherwise specified in an
NIH solicitation, Internet addresses (URLs) should not be used to
provide information necessary to the review because reviewers are under
no obligation to view the Internet sites. Reviewers are cautioned that
their anonymity may be compromised when they directly access an
Internet site.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT
The Office of Management and Budget (OMB) Circular A-110 has been
revised to provide public access to research data through the Freedom
of Information Act (FOIA) under some circumstances. Data that are (1)
first produced in a project that is supported in whole or in part with
Federal funds and (2) cited publicly and officially by a Federal agency
in support of an action that has the force and effect of law (i.e., a
regulation) may be accessed through FOIA. It is important for
applicants to understand the basic scope of this amendment. NIH has
provided guidance at:
<a href="//grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm">http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm</a>.
Applicants may wish to place data collected under this PA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application
should include a description of the archiving plan in the study design
and include information about this in the budget justification section
of the application. In addition, applicants should think about how to
structure informed consent statements and other human subjects
procedures given the potential for wider use of data collected under
this award.
APPLICATION PROCEDURES
The PHS 398 research grant application instructions and forms (rev.
5/2001) at <a href="//grants.nih.gov/grants/funding/phs398/phs398.html">http://grants.nih.gov/grants/funding/phs398/phs398.html</a> must
be used in applying for these grants and will be accepted at the
standard application deadlines (<a href="//grants.nih.gov/grants/dates.htm">http://grants.nih.gov/grants/dates.htm</a>)
as indicated in the application kit. This version of the PHS 398 is
available in an interactive, searchable format. Although applicants are
strongly encouraged to begin using the 5/2001 revision of the PHS 398
as soon as possible, the NIH will continue to accept applications
prepared using the 4/1998 revision until January 9, 2002. Beginning
January 10, 2002, however, the NIH will return applications that are
not submitted on the 5/2001 version. For further assistance contact
GrantsInfo, Telephone 301/710-0267, Email: <a href="/cdn-cgi/l/email-protection#632411020d17102a0d050c230d0a0b4d040c15"><span class="__cf_email__" data-cfemail="82c5f0e3ecf6f1cbece4edc2ecebeaace5edf4">[email&#160;protected]</span></a>.
Applicants planning to submit an investigator-initiated new (type 1),
competing continuation (type 2), competing supplement, or any
amended/revised version of the preceding grant application types
requesting $500,000 or more in direct costs for any year are advised
that he or she must contact the Institute or Center (IC) program staff
before submitting the application, i.e., as plans for the study are
being developed. Furthermore, the application must obtain agreement
from the IC staff that the IC will accept the application for
consideration for award. Finally, the applicant must identify, in a
cover letter sent with the application, the staff member and Institute
or Center who agreed to accept assignment of the application.
This policy requires an applicant to obtain agreement for acceptance of
both any such application and any such subsequent amendment. Refer to
the NIH Guide for Grants and Contracts, March 20, 1998 at
<a href="//grants.nih.gov/grants/guide/notice-files/not98-030.html">http://grants.nih.gov/grants/guide/notice-files/not98-030.html</a>.
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS
The modular grant concept establishes specific modules in which direct
costs may be requested as well as a maximum level for requested
budgets. Only limited budgetary information is required under this
approach. The just-in-time concept allows applicants to submit certain
information only when there is a possibility for an award. It is
anticipated that these changes will reduce the administrative burden
for the applicants, reviewers and NIH staff. The research grant
application form PHS 398 (rev. 5/2001) at
<a href="//grants.nih.gov/grants/funding/phs398/phs398.html">http://grants.nih.gov/grants/funding/phs398/phs398.html</a> is to be used
in applying for these grants, with modular budget instructions provided
in Section C of the application instructions. Applicants are
permitted, however, to use the 4/1998 revision of the PHS 398 for
scheduled application receipt dates until January 9, 2002. If you are
preparing an application using the 4/1998 version, please refer to the
step-by-step instructions for Modular Grants available at
<a href="//grants.nih.gov/grants/funding/modular/modular.htm">http://grants.nih.gov/grants/funding/modular/modular.htm</a>. Additional
information about Modular Grants is also available on this site.
The title and number of the program announcement must be typed on line
2 of the face page of the application form and the YES box must be
marked.
Submit a signed, typewritten original of the application, including the
Checklist, and five signed photocopies in one package to:
CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
6701 ROCKLEDGE DRIVE, ROOM 1040, MSC 7710
BETHESDA, MD 20892-7710
BETHESDA, MD 20817 (for express/courier service)
REVIEW CONSIDERATIONS
Applications will be assigned on the basis of established PHS referral
guidelines. Applications will be evaluated for scientific and
technical merit by an appropriate scientific review group convened in
accordance with the standard NIH peer review procedures. As part of
the initial merit review, all applications will receive a written
critique and undergo a process in which only those applications deemed
to have the highest scientific merit, generally the top half of
applications under review, will be discussed, assigned a priority
score, and receive a second level review by the appropriate national
advisory council or board.
Review Criteria
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health.
In the written comments reviewers will be asked to discuss the
following aspects of the application in order to judge the likelihood
that the proposed research will have a substantial impact on the
pursuit of these goals. Each of these criteria will be addressed and
considered in assigning the overall score, weighting them as
appropriate for each application. Note that the application does not
need to be strong in all categories to be judged likely to have major
scientific impact and thus deserve a high priority score. For example,
an investigator may propose to carry out important work that by its
nature is not innovative but is essential to move a field forward.
(1) Significance: Does this study address an important problem? If
the aims of the application are achieved, how will scientific knowledge
be advanced? What will be the effect of these studies on the concepts
or methods that drive this field?
(2) Approach: Are the conceptual framework, design, methods, and
analyses adequately developed, well-integrated, and appropriate to the
aims of the project? Does the applicant acknowledge potential problem
areas and consider alternative tactics?
(3) Innovation: Does the project employ novel concepts, approaches or
method? Are the aims original and innovative? Does the project
challenge existing paradigms or develop new methodologies or
technologies?
(4) Investigator: Is the investigator appropriately trained and well
suited to carry out this work? Is the work proposed appropriate to the
experience level of the principal investigator and other researchers
(if any)?
(5) Environment: Does the scientific environment in which the work
will be done contribute to the probability of success? Do the proposed
experiments take advantage of unique features of the scientific
environment or employ useful collaborative arrangements? Is there
evidence of institutional support?
In addition to the above criteria, in accordance with NIH policy, all
applications will also be reviewed with respect to the following:
o The adequacy of plans to include both genders, minorities and their
subgroups, and children as appropriate for the scientific goals of the
research. Plans for the recruitment and retention of subjects will
also be evaluated.
o The reasonableness of the proposed budget and duration in relation
to the proposed research
o The adequacy of the proposed protection for humans, animals or the
environment, to the extent they may be adversely affected by the
project proposed in the application.
o The adequacy of the proposed plan to share data.
AWARD CRITERIA
Award criteria that will be used to make award decisions include:
o scientific merit (as determined by peer review)
o availability of funds
o programmatic priorities.
Applications will compete for available funds with all other
recommended applications. The following will be considered in making
funding decisions: Quality of the proposed project as determined by
peer review, availability of funds, and program priority.
INQUIRIES
Inquiries are encouraged. The opportunity to clarify issues or
questions from
potential applicants is welcome.
Direct inquiries regarding programmatic issues to:
Jonathan D. Pollock, Ph.D.
Division of Neuroscience and Behavioral Research
National Institute on Drug Abuse
6001 Executive Boulevard, Room 4282, MSC 9555
Bethesda, MD 20892-9555
Telephone: 301-443-6300
FAX: 301-594-6043
Email: <a href="/cdn-cgi/l/email-protection#b3d9c3828b80c1f3dddadb9dd4dcc5"><span class="__cf_email__" data-cfemail="7f150f4e474c0d3f11161751181009">[email&#160;protected]</span></a>
Direct inquiries regarding fiscal matters to:
Gary Fleming, J.D., M.A.
Grants Management Branch
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3131, MSC 9541
Bethesda, MD 20892-9541
Telephone: 301-443-6710
FAX: 301-594-6847
Email: <a href="/cdn-cgi/l/email-protection#84e3e2b2f7c4eaedecaae3ebf2"><span class="__cf_email__" data-cfemail="8cebeabaffcce2e5e4a2ebe3fa">[email&#160;protected]</span></a>
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic Assistance
No. 93.279. Awards are made under authorization of sections 301 and
405 of the Public Health Service Act as amended (42 USC 241 and 284)
and administered under NIH grants policies and Federal Regulations 42
CFR 52 and 45 CFR Parts 74 and 92. This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.
The PHS strongly encourages all grant and contract recipients to
provide a smoke-free workplace and promote the non-use of all tobacco
products. In addition, Public Law 103-227, the Pro-Children Act of
1994, prohibits smoking in certain facilities (or in some cases, and
portion of a facility) in which regular or routine education, library,
day care, health care or early childhood development services are
provided to children. This is consistent with the PHS mission to
protect and advance the physical and mental health of the
American people.
</pre>
<P><HR><P>
<A HREF="/grants/guide/WeeklyIndex.cfm?WeekEnding=10-19-01">Weekly TOC for this Announcement</A><br>
<A HREF="/grants/guide/index.html">NIH Funding Opportunities and Notices</A>
<!-- Start DHHSFooter.cfm 3/13/2008-->
<br><br>
<hr>
<table align="center">
<tr><td align="center" colspan="6"><span class='st_facebook_hcount' displayText='Facebook'></span>
<span class='st_twitter_hcount' displayText='Tweet'></span>
<span class='st_linkedin_hcount' displayText='LinkedIn'></span>
<span class='st_email_hcount' displayText='Email'></span>
<span class='st_sharethis_hcount' displayText='ShareThis'></span><br></td></tr>
<tr>
<td>
<div align="center"><a href="/grants/oer.htm"><img src="/images7/nih-oer-logo.jpg" alt="NIH Office of Extramural Research Logo" usemap="#Map2" border="0"></a></div>
<map name="Map2" id="Map2">
<area shape="rect" coords="89,17,359,39" href="http://www.nih.gov" />
<area shape="rect" coords="91,39,286,58" href="http://grants.nih.gov/grants/oer.htm" />
<area shape="rect" coords="3,5,78,55" href="http://grants.nih.gov/grants/oer.htm" />
</map>
</td>
<td width="20">&nbsp;</td>
<td>
<a href="https://www.hhs.gov/"><img src="/images7/dhhs_sm.gif" width="36" height="37" border="0" alt="Department of Health and Human Services (HHS) - Home Page" long desc="Logo, circular in shape, depicting an American eagle in-flight with stylized profiles of human faces appearing on the trailing edge of the wings. The perimeter of the logo is encircled with the words 'Department of Health and Human Services U S A'"></a>
</td>
<td valign="middle">
<font size="-1" face="Arial">Department of Health<br>and Human Services (HHS)</font>
</td>
<td width="20">&nbsp;</td>
<td>
<a href="https://www.usa.gov/"><img src="/images7/USA_Gov_logo.gif" border="0" alt="USA.gov - Government Made Easy" long desc="Logo,- the words 'USA.gov - Government Made Easy' with single streaking star above the logo"></a>
</td>
</tr>
<tr align="center">
<td colspan="7">
</td>
</tr>
<tr align="center">
<td colspan="7">
<span style="color:#6E6E6E; font-size:1.0em; font-family: 'Trebuchet MS', Arial, Helvetica, sans-serif">NIH... Turning Discovery Into Health<sup>&reg;</sup></span><br><br>
</td>
</tr>
</table>
<!-- End DHHSFooter.cfm 3/13/2008-->
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></BODY>
</HTML>